|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Liquid-liquid extraction of biomolecules: an overview and update of the main techniques 显示文摘 | Priscila G Mazzola Andre M Lopes Francislene A Hasmann | 2008 | Journal of Chemical Technology and Biotechnology2008，83，2： | 1 |
| 2 | Fit-for purpose use of mouse models to improve predictivity of cancer therapeu- tics evaluation 显示文摘 | Wartha K Herting F Hasmann M | 2014 | Pharmacology & Therapeutics2014，142，3： | 1 |
| 3 | FK866, a highly specific noncompetitive inhibitor of nicotinamide phospho ribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis 显示文摘 | Hasmann M I Schemainda | 2003 | Cancer Res2003，63，21： | 1 |
| 4 | Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement- dependent anti- tumor activity of trastuzumab and pertuzumab 显示文摘 | Mamidi S Cinci M Hasmann M | 2013 | Mol Oncol2013，7，3： | 1 |
| 5 | FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyl- transferase, represents a novel mechanism for induction of tumor cell apoptosis 显示文摘 | HASMANN M SCHEMA1NDA I | 2003 | Cancer Res2003，63，21： | 1 |
| 6 | FK866,a highly specific noncompeti-tive inhibitor of nicotinamide phosphoribosyltransferase,representsa novel mechanismfor induction of tumor cell apoptosis显示文摘 | Hasmann M Schemainda I | 2003 | Canc-er Res2003，63，21： | 1 |
| 7 | Lipoplex mediated silencing of membrane regulators(CD46, CD55 and CD59)enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab显示文摘 | Mamidi S Cinci M Hasmann M | 2013 | Mol Oncol2013，7，3： | 1 |
| 8 | Preclinical data for Droloxifene显示文摘 | Hasmann M Rattel B Loser R | 1994 | Cancer Lett1994，84，2： | 1 |
| 9 | Angiotensinogen: an acute- phase protein? 显示文摘 | Soden M Klett C Hasmann T | 1994 | Hypertension1994，23，1： | 1 |
| 10 | FK866, a highly specific noncompeti - tive inhibitor of nicotinamide phosphoribosyltransferase, represent- sa novel mechanism for induction of tumor cell apoptosis 显示文摘 | Hasmann M Schemainda I | 2003 | Cancer Res2003，63，21： | 1 |
| 11 | FK866,a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase,represents a novel mechanism for induction of tumor cell apoptosis显示文摘 | Hasmann M Schemainda I | 2003 | Cancer Res2003，63，21： | 1 |
| 12 | MLipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59 ) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab显示文摘 | Mamidi S Cinci M Hasmann M | 2013 | Mol Oncol2013，7，3： | 1 |
| 13 | FK866, a highly specific noncom- petitive inhibitor of nicotinamide phosphoribosyltransferase, re- presents a novel mechanism for induction of tumor cell apopto- sis显示文摘 | Hasmann M Schemainda I | 2003 | Cancer Res2003，63，： | 1 |
| 14 | Intracellular localization,vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug resistant gastric carcinoma EPG85- 257 cells 显示文摘 | Seidel A Hasmann M Loser R | 1995 | Virchows Arch1995，426，： | 1 |
| 15 | Lipoplex mediated silencing of membrane regulators ( CD46, CD55 and CD59 ) enhances complement- dependent anti-tumor activity of trastuzumab and pertuzumab 显示文摘 | Mamidi S Cinei M Hasmann M | 2013 | Mol Oncol2013，7，3： | 1 |
| 16 | FK866,a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase,represents a novel mechanism for induction of tumor cell apoptosis显示文摘 | Hasmann M Schemainda I | 2003 | Cancer Res2003，63，21： | 1 |
| 17 | FK866, a highly specific noncompeti- tive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis 显示文摘 | Hasmann M Schemainda I | 2003 | Cancer Res2003，63，21： | 1 |
| 18 | FK866,a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyl transferase,represents a novel mechanism for induction of tumor cell apoptosis显示文摘 | Hasmann M Schemainda I | 2003 | Cancer Res2003，63，21： | 1 |
| 19 | Perluzumab increases 17-AAG-induced degradation of ErbB2, and this effect is lhrther increased by combining pertuztmaab with trastuzumab显示文摘 | Hughes J B Rodland M S Hasmann M | 2012 | Pharmaceuticals2012，5，7： | 1 |
| 20 | Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy显示文摘 | Friess T Scheuer W Hasmann M | | 0，，14： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员